Background
==========

The ageing of our populations, with the increasing prevalence of physical and cognitive disorders associated with age, poses a major burden on society \[[@B1]\]. Making an impact on this disability burden requires an understanding of the risk and protective factors for age-related cognitive decline, frailty and chronic disease. The optimal approach to study this involves the longitudinal examination of population-based ageing cohorts. There are many such studies currently ongoing internationally, but there is considerable inconsistency in the results produced \[[@B2]\] and further systematic examination of the existing evidence is required to determine findings which are robust.

Some of the variation in prevalence rates and risk factors identified across studies may be associated with regional and/or ethnic differences. For example, rates of non-amnestic mild cognitive impairment (MCI) are reported to be higher in blacks than whites from a similar geographical location, even when controlling for sex and education \[[@B3]\]. However, a significant proportion of the variance between studies is likely attributable to differences in methodology, including differences in the assessment tools and performance criteria used for diagnosing cognitive disorders. Indeed, small but theoretically valid changes to how objective cognitive impairment was operationally defined led to greatly elevated prevalence rates, from 4% to 70% \[[@B4]\]. Similarly, using different criteria for the diagnosis of dementia can result in vastly different prevalence figures \[[@B5]\].

There are a number of approaches for overcoming methodological differences and other sources of heterogeneity so that studies can be more accurately compared and true differences identified. These include the use of standardised protocols, meta-analysis, and harmonisation of data \[[@B6]\]. The use of standardised or even similar protocols is a rare feature of existing collaborations (the 10/66 Dementia Research Group is one exception \[[@B7]\]), and meta-analysis is limited to published results. In contrast, data harmonisation offers the potential to explore both existing and novel research questions by a cost-effective use of previously-collected data.

Harmonising data across studies to create a single, large database helps to minimise the influence of both study-level (e.g., methodology) and individual level (e.g., demographic) factors, while also enabling these to be explored as potential contributors to differences in results \[[@B8],[@B9]\]. Other advantages include increased statistical power for detecting effects, and the inherent replication and enhanced generalisability associated with using heterogeneous samples and methodologies \[[@B8]\].

COSMIC (Cohort Studies of Memory in an International Consortium) is a recently established endeavour that aims to bring together cohort studies of cognitive ageing internationally in order to facilitate a better understanding of the determinants of cognitive ageing and neurocognitive disorders. The two main objectives of this project are to:

1\. Harmonise shared, non-identifiable data from cohort studies that longitudinally examine change in cognitive function and the development of dementia in older individuals (60+ years).

2\. Perform joint or mega-analyses using combined, harmonised data sets that yield collated results with enhanced statistical power, in addition to comparisons across geographical regions, ethnicities and sociocultural groups.

Other collaborations bringing together cohort studies of ageing include the genetics-focused CHARGE (Cohorts for Heart and Aging Research in Genomic Epidemiology) \[[@B10]\] and ENIGMA (Enhancing NeuroImaging Genetics through Meta-Analysis) \[[@B11]\]. Consortia with a particular interest in cognitive ageing include the UK-based HALCyon (Healthy Ageing across the Life Course) \[[@B12]\], the primarily Europe-based CHANCES (Consortium on Health and Ageing: Network of Cohorts in Europe and the United States) \[[@B13]\], the Australian-based DYNOPTA (Dynamic Analyses to Optimise Ageing) \[[@B14]\], and the IALSA (Integrative Analysis of Longitudinal Studies on Aging) network \[[@B15]\], which has member studies from Europe, North America and Australia. None of these consortia have any studies from Asia, where the current and future number of people with dementia is estimated to be greater than that of Europe and the Americas combined \[[@B1]\]. COSMIC hopes to distinguish itself by being a truly international effort comprising studies with a clinical and biomedical focus from Asia, Europe, the Americas, and Oceania. COSMIC was established in 2012, with progress reported in 2013 \[[@B16]\].

Methods/design
==============

Membership
----------

Studies are eligible to participate in COSMIC if they meet the following membership criteria:

1\. Are epidemiological, and therefore population-based.

2\. Have a minimum sample size of 500.

3\. Examine individuals aged 60 years and over.

4\. Are longitudinal, with a minimum of two assessments.

5\. Include assessment of cognitive function as an important, if not central, objective.

6\. The outcome measures include dementia and/or cognitive impairment and/or cognitive decline.

Official enrolment in COSMIC involves a lead investigator having signed a memorandum of understanding that entails a willingness to share non-identifiable raw and/or processed data for joint or mega-analyses. Studies that, for institutional or other reasons, are unable to provide raw and/or processed data may participate in COSMIC as provisional members, if willing to provide results of in-house analyses conducted using COSMIC protocols. At the time of writing there are 14 officially enrolled and 3 provisional members of COSMIC. These studies, and their key demographic characteristics, are shown in Table [1](#T1){ref-type="table"}. It is intended that the overall sample size and range of geographical regions and ethnicities represented be extended even further, and thus we ask that any study meeting the eligibility criteria consider contacting us to become a member of COSMIC. Studies from Africa, South America and Eastern Europe are particularly encouraged to join.

###### 

COSMIC member studies

                                  **Study**                                  **Country**   **Sample size**   **Age range**   **Males(%)**       **Main races/ethnicities**        **Start and end date**                                            **Key reference(s)**
  ------------------------------------------------------------------------- ------------- ----------------- --------------- -------------- ------------------------------------- ------------------------ ---------------------------------------------------------------------------------------------------------
                  Canadian Study of Health and Aging (CSHA)                    Canada           10263           65-102            43                     Caucasian                      1991-2002                                           CSHA Working Group (1994) \[[@B17]\]
                Chinese Longitudinal Ageing Study (CLAS)^\*^                    China           3514              60+             44                      Chinese                         2010-                                                 Xiao et al. (2013) \[[@B18]\]
               Cognitive Function and Ageing Studies (CFAS)^†^                   UK             13004             65+             40                     Caucasian                        1991-                                                Brayne et al. (2006) \[[@B19]\]
                       Einstein Aging Study (EAS)^\*^                            USA            1956            66-104            39            Caucasian/African American                1993-                                                 Katz et al. (2012) \[[@B3]\]
   Etude Santé Psychologique Prévalence Risques et Traitement (ESPRIT)^\*^     France           2268              65+             42                   Not recorded                       1999-                                               Ritchie et al. (2010) \[[@B20]\]
                       Framingham Heart Study (FHS)^†^                           USA          15328^‡^            5+              50                     Caucasian                        1948-            Dawber & Kannel (1958) \[[@B21]\]; Feinleib et al. (1975) \[[@B22]\]; Splansky et al. (2007) \[[@B23]\]
         Hong Kong Memory and Ageing Prospective Study (HK-MAPS)^\*^          Hong Kong          787              60+             46                      Chinese                         2005-                                                 Wong et al. (2013) \[[@B24]\]
     Korean Longitudinal Study on Cognitive Aging and Dementia (KLOSCAD)     South Korea        6479              60+             44                      Korean                          2009-                                                 Kim et al. (2013) \[[@B25]\]
                    Mayo Clinic Study of Aging (MCSA)^†^                         USA            4000             50-89            50                     Caucasian                        2004-                                               Roberts et al. (2008) \[[@B26]\]
          Monongahela Valley Independent Elders Survey (MoVIES)^\*^              USA            1681              65+             42                     Caucasian                      1987-2002                                             Ganguli et al. (2000) \[[@B27]\]
        Personality and Total Health (PATH) Through Life Project^\*^          Australia         2551             60-64            52                     Caucasian                        2001-                                                Anstey et al. (2012) \[[@B28]\]
          Singapore Longitudinal Ageing Studies (SLAS) I and II^\*^           Singapore         5748             54-98            37                      Chinese                         2003-                                          Feng et al. (2010, 2013) \[[@B29],[@B30]\]
               Sydney Memory and Ageing Study (Sydney MAS)^\*^                Australia         1037              70+             45                     Caucasian                        2005-                                               Sachdev et al. (2010) \[[@B31]\]
                               Tajiri Project                                   Japan           1654              65+             42                     Japanese                       1998-2005                                              Meguro et al. (2002) \[[@B32]\]
      Washington Heights Inwood and Columbia Aging Project (WHICAP)^\*^          USA            4577            63-103            32        Hispanic/African American/Caucasian           1989-                                                 Tang et al. (2001) \[[@B33]\]
         ZARADEMP Project (ZARAgoza DEMentia DEPression Project)^\*^            Spain           4803              55+             42                     Caucasian                        1994-                                                 Lobo et al. (2005) \[[@B34]\]

^\*^Data for the first project have been made available.

^†^Provisional member.

^‡^Including 3 generations (Original cohort, Offspring, Grandchildren) and separate Omni cohort of 900 ethnic minority participants.

Organisation
------------

COSMIC has a Research Steering Committee comprising one representative from each participating study, generally the lead investigator or a delegate. The primary functions of the Research Steering Committee are:

1\. To develop guidelines for the inclusion and exclusion of studies.

2\. To provide rules of participation and guidelines for the roles and responsibilities of the participating studies.

3\. To approve Workgroups.

4\. To select topics of interest.

5\. To provide overall analytic strategies.

6\. To develop rules for publication, including authorship.

7\. To develop rules for the protection of intellectual property, when relevant.

8\. To seek funds to support COSMIC.

Meetings
--------

An initial meeting of many (now member) study leaders on July 16, 2012 in Vancouver supported the official establishment of COSMIC. Potential projects, both initial and more long-term, and the steps needed to progress these were among the topics discussed. A subsequent meeting comprising many of the Research Steering Committee members was held on July 15, 2013 in Boston.

Website
-------

A website has been established that contains a description of COSMIC and summaries of the member studies (<http://www.cheba.unsw.edu.au/group/cosmic>). This website is intended to serve as an avenue for presenting and preserving COSMIC project protocols and results, and will potentially house data restricted by password to COSMIC members. The Sydney team are currently responsible for the development and maintenance of the COSMIC website.

Ethics
------

The overall COSMIC project has been approved by the Human Research Ethics Committee of the University of New South Wales, Sydney. Member studies are responsible for obtaining approval (if considered necessary) from their local institutional review board for the sharing of data. However, de-identified data are not considered Protected Health information by the National Institute of Health of the USA. A protocol for the de-identification of data has been developed.

Discussion
==========

Challenges
----------

General challenges facing large, international consortia have been previously described (e.g., by CHARGE \[[@B10]\]). These include a potential need for additional funding to prolong the use of study data beyond initial anticipations, and timely and effective communication among members across different countries.

More specific to COSMIC are challenges associated with harmonisation, many of which have also been previously described \[[@B9],[@B35]\]. The major challenge of harmonisation stems from differences between studies in the measurement instruments used and/or differences in how questions from similar instruments are worded and responses provided and categorised, including the effect of language and culture. Attempts to maximise the number of studies contributing to a final dataset can require that complex information from some studies be simplified (e.g., converted from a continuous measure to a categorical scale). There is a potential reduction in validity involved in simplifying data, but there are mechanisms by which this can be tested and/or quantified \[[@B9]\].

Meeting the objectives of COSMIC will require various data types to be harmonised, but data relating to cognitive outcomes such as impairment and decline are likely to be the most challenging (i.e., more so than demographic and health-related variables). COSMIC member studies have operationally defined cognitive outcomes in vastly different ways. For example, for the purposes of diagnosing MCI, cognitive impairment has been variously defined as abnormal scores on the memory items of two cognitive status instruments (Mini-Mental State Examination and Geriatric Mental State Schedule) in the Zaragoza Dementia Depression Project \[[@B36]\], and as a score on any measure from a comprehensive neuropsychological battery 1.5 or more standard deviations below published normative values in the Sydney Memory and Ageing Study \[[@B31]\]. Different studies have used different neuropsychological test batteries, but even when similar cognitive tests have been used it is often the case that different versions have been used or the tests have been administered in a non-standard way. An added complication is the need to reconcile differences in the data while giving appropriate consideration to relevant demographic effects, including those associated with gender and education.

First project
-------------

The aim of the first COSMIC project is to compare the baseline prevalence of MCI across the COSMIC member cohorts and the different regions and ethnicities represented by these. The project is currently underway, and is being coordinated by the Sydney team. A questionnaire was developed and promulgated, with the information provided guiding a subsequent request for data from the studies on:

1\. Demographics.

2\. Sample representativeness.

3\. Neuropsychological test performance.

4\. Functional test scores.

5\. Memory/cognitive complain/concerns.

6\. Criteria used for MCI.

The receipt of data was followed by communication with data managers and/or study leaders to clarify the nature of data (e.g., the particular neuropsychological test used or manner of administration) and/or to ask that further data be provided (e.g., the individual items from a functional test scale in addition to a total score originally provided). Data from 11 studies have been made available for this project (see Table [1](#T1){ref-type="table"}), and there is a total sample size of more than 23,000 non-demented individuals aged 60 and older.

Some demographic variables have been harmonised. All studies provided age in years, and harmonising sex only required some recoding to a common scale (female = 0; male = 1). Education was less straightforward. A four-level categorical scale of the highest level of education achieved (Less than high school completion, High school completion, Technical or college diploma, University degree) was chosen as the most appropriate common measure, and to which various other categorical formats or years of formal education were transformed (see Additional file [1](#S1){ref-type="supplementary-material"} for the protocol). Data were provided in the harmonised format by the studies themselves, or later transformed from the original variable by the project coordinators.

The next step will be to harmonise the data needed to make classifications of MCI. The participating studies have published widely varying rates of MCI, from as low as 3.2% for the Monongahela Valley Independent Elders Survey \[[@B37]\] to 34.8% for the Sydney Memory and Ageing Study \[[@B31]\]. Differences between the studies in how MCI diagnoses were made have undoubtedly contributed to the varying prevalence rates \[[@B4]\], and minimising this requires the harmonisation of data informing the four generally accepted criteria for MCI:

1\. Absence of dementia.

2\. No or minimal functional impairment.

3\. Objective cognitive impairment.

4\. Memory complaint or concern \[[@B38],[@B39]\].

Future projects
---------------

A number of future projects utilising COSMIC data are currently planned, and aim to make comparisons across COSMIC cohorts, countries and ethnic groups of:

1\. Risk and protective factors for MCI.

2\. Rates of cognitive decline.

3\. Biomarkers (e.g., blood, genetic and MRI-derived) of MCI and dementia.

Many of the existing member studies have relevant data to contribute to these projects. It is expected that additional projects will address more refined and specific topics addressing the overall objectives of COSMIC. This could include identifying and comparing rates of decline within particular cognitive domains, and establishing associations between untreated hypertension or non-traditional risk factors and cognitive decline. Projects like these will be enabled and facilitated by growing the COSMIC membership base to ensure that there are sufficient relevant data on variables not collected by all studies.

Extended Implications of COSMIC
-------------------------------

The mechanisms for harmonising measures developed by COSMIC could produce standardised ways of collecting and reporting data that facilitate the comparability of longitudinal studies of ageing. This includes previous or existing studies, for which data could be reformatted and further analysed. It may also guide the choice of measures used or type of data collected by future studies, for which the capacity to directly compare results with those of many other cohorts would greatly enhance their interpretability and relevance.

There is also the potential for the COSMIC database to be made available to non-consortium researchers via the website, following consortia-based publications and with the approval of the Research Steering Committee. The scientific benefits of making large databases available to researchers worldwide are demonstrated by the more than 250 publications reported to have arisen from the sharing of ADNI (Alzheimer\'s Disease Neuroimaging Initiative) data across the internet \[[@B40]\].

With these, and potentially further extended implications and uses of COSMIC data, member studies can be confident that their data are being fully utilised and that they are contributing to a truly global effort to understand and combat the problems associated with cognitive ageing, MCI and dementia.

Conclusion
==========

The COSMIC project is a truly international effort to inform the epidemiology of cognitive disorders associated with advanced age by identifying risk factors and biomarkers that are common as well as unique. It has the potential to transform our understanding of the epidemiology of cognitive ageing and have a world-wide impact on promoting successful ageing.
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